Evidence map›Paper›PMID 39975696›Full record

ArticleFrontiers in public health2024

Systematic analysis and prediction of the burden of Alzheimer's disease and other dementias caused by hyperglycemia.

Dongying He, Manting Liu, Yujin Tang, Xiaona Tian, Lisi Zhou, Yizhen Chen, Xiaoxia Liu

Abstract read
In one paragraph

Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dongying HeThe Eighth Clinical Medical College of Guangzhou University of Chinese Medicine, Foshan, China.
Manting LiuGraduate School, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yujin TangFoshan Hospital of Traditional Chinese Medicine, Foshan, China.
Xiaona TianDepartment of Endocrinology, Zhongshan People's Hospital (ZSPH), Zhongshan, China.
Lisi ZhouGraduate School, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yizhen ChenClinical Medical College, Jiangmen Wuyi Traditional Chinese Medicine Hospital, Jiangmen, China.
Xiaoxia LiuThe Eighth Clinical Medical College of Guangzhou University of Chinese Medicine, Foshan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Alzheimer's disease and other dementias (ADOD) pose a significant and escalating global public health challenge, particularly among the aging populations. Emerging evidence has identified high fasting plasma glucose (HFPG) as a major modifiable risk factor for ADOD, linking impaired glucose metabolism to cognitive decline and neurodegeneration. Despite this association, the comprehensive impact of HFPG on the global burden of ADOD has not been fully elucidated. Understanding the extent to which HFPG contributes to ADOD is crucial for developing targeted interventions and optimizing healthcare resource allocation to address this growing concern. Methods: Using Global Burden of Disease data (GBD 2021), we analyzed the global HFPG-related ADOD burden from 1990 to 2021 using an age-period-cohort framework and predicted trends for 2050. A Shiny platform was developed to visualize the disease burden and trends across 204 countries and regions. Results: In 2021, approximately 15% of ADOD deaths and disability-adjusted life years (DALYs) were attributed to HFPG, a 271.05% increase from 1990. The incidence rate rose from 47.07 to 66.42, indicating poor control. The mortality rate from HFPG-ADOD increased by 305.81%. The primary burden was among the 80-84 age group. Trends in ASDR and ASMR showed an increase across most SDI regions, except Low SDI. Decomposition analysis and the APC model indicated poor control in high SDI regions due to aging populations over the past 5 years. By 2050, the global prevalence is projected to reach 1,003,018.047 (26124.40377, 12114480.49), with 345,342.5738 (1431.57781, 6022119.213) males and 657,675.4731 (24692.82596, 6092361.28) females. The Shiny platform predicts a yearly increase in ASDR and ASMR for HFPG-ADOD in China, which is consistent with GBD platform trends. The platform is accessible at http://116.196.73.86:3838/GBD/HFPG-ADOD/. Conclusion: The global burden of HFPG-related ADOD has been increasing, even in high SDI regions, over the past 5 years and is expected to continue rising until 2050. Implementing appropriate health policies to mitigate this trend could significantly reduce the substantial burden caused by HFPG-induced ADOD. Promoting the use of the Shiny prediction platform will contribute significantly to global healthy aging.

Indexed as

Alzheimer DiseaseCost of IllnessDementiaHyperglycemiaAgedAged, 80 and overDisability-Adjusted Life YearsFemaleGlobal Burden of DiseaseGlobal HealthHumansIncidenceMaleMiddle AgedRisk FactorsAlzheimer’s diseasedementiadisease burdenfrontier analysispredictive analysis

Identifiers

PMID39975696
PMCPMC11835675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.